摘要
肝细胞癌(hepatocellular carcinoma,HCC)(简称肝癌)是严重威胁人类健康的重大疾病,位列世界第三位的癌症死亡原因,我国恶性肿瘤病死率的第二位。肝癌的发病率存在着性别差异,已有大量研究雌激素在肝癌形成中的作用,并且认为雌激素在肝癌的形成过程中起到保护作用。有研究表明雌激素通过抑制IL-6的表达进而减少肝癌的发生。IL-6与HGF在肝癌形成过程中均有重要的促进作用,雌激素与这些因子也存在着重要的联系。目前需要深入探索新颖的辅助治疗方法来提高肝癌患者的生存率。
Hepatocellular carcinoma is a major disease for serious threat to human health, ranked third in the world of cancer causes of death and second in China' s in cancer mortality. There are gender differences in the incidence of HCC and numerous studies on estrogen' s role in the formation of HCC, and the formation of estrogen in the liver plays a protective role during the hepatocarcinogenesis. Some studies have shown estrogen inhibiting the expression of interleukin-6 thereby reducing the incidence of HCC. IL-6 and HGF have an important role in promoting HCC formation process, estrogen and these factors have are also important links. Now require in-depth exploration of novel adjuvant therapy is required to improve the survival rate of patients with HCC.
出处
《国际外科学杂志》
2010年第5期332-334,共3页
International Journal of Surgery
基金
2009年国家自然基金资助项目(No.30972893)